RALA and benign prostatic hyperplasia: As shown in Figure 1A, among 174 PCa sera, the autoantibody levels to RalA (median) in the NHS were significantly lower than in PCa (0.053 vs 0.138; P < 0.001) and BPH (0.053 vs 0.132; P < 0.005) groups.